A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Amgen
Seqker Biosciences, Inc.
Novartis
AstraZeneca
Benfovir AG
Karyopharm Therapeutics Inc
Alume Biosciences, Inc.
NaviFUS Corporation
Fresenius Kabi Taiwan Ltd.
Koelis
Tasly Pharmaceutical Group Co., Ltd
Lumos Pharma
Celgene
Nanjing Leads Biolabs Co.,Ltd
Boehringer Ingelheim
iOnctura
Almirall, S.A.
Pfizer
Immorna Biotherapeutics, Inc.
AbbVie
Coherus Oncology, Inc.
Dragonfly Therapeutics
Takeda
Merck Sharp & Dohme LLC
NeoImmuneTech
Varian, a Siemens Healthineers Company
AstraZeneca
Pfizer
Inmune Bio, Inc.
Lokon Pharma AB
Bristol-Myers Squibb
AI Labs Group S.L
Boehringer Ingelheim
AstraZeneca
Janssen Research & Development, LLC
Adaptimmune
EMD Serono
Cytovation AS
Advanced Accelerator Applications
Boehringer Ingelheim
Boehringer Ingelheim
Bristol-Myers Squibb
AbbVie
Meryx, Inc.
Revolution Medicines, Inc.
Pfizer
Werewolf Therapeutics, Inc.
Eli Lilly and Company
Klein Buendel, Inc.
Reveal Pharmaceuticals Inc.